COMPUTEX 2021 Hybrid Embarks on an Intelligent Journey with AI Tech Giants
27.4.2021 09:41:00 EEST | Business Wire | Press release
According to IDC, worldwide revenues for the artificial intelligence (AI) market are expected to break the USD 500 billion mark. As AI continues to transform daily lives with various applications, industries are actively introducing AI technologies into operations in the drive to optimize business processes. As the global leading ICT tradeshows, COMPUTEX teams up with major international technology companies to showcase the AI ecosystem and deliver an exceptional intelligent exhibition experience.
AI is the ‘it’ topic at COMPUTEX 2021 Hybrid
COMPUTEX organizer, the Taiwan External Trade Development Council (TAITRA), states that AI is one of the hottest topics at COMPUTEX 2021 Hybrid this year, especially as 5G providers inject new momentum into a variety of developments in AI and IoT technology applications.
At the #COMPUTEXVirtual online exhibition, GIGABYTE will showcase extensive product lines based on multiple processor architectures for a variety of applications. By empowering the CPUs with external accelerators such as ASICs, FPGAs, and GPUs, GIGABYTE offers complete solutions for AI learning and AI inferencing, expediting the actualization of the AIoT.
Supermicro will showcase the latest multi-GPU optimized systems that deliver advanced solutions to AI, Deep Learning, HPC, 3D-Graphics Visualization, Desktop Virtualization, and Video Streaming applications.
On the other hand, GARAOTUS from the on-premise HPC cloud solution provider, SYSTEX, will offer HPC and AI solutions with cloud-native that simplify the customers’ business workflow, increase productivity, and reduce the labor-intensive burden to accelerate innovation.
AI has acted as the main driver of emerging technologies, the COMPUTEX Forum will focus on AI’s developments and trends as one of the topics. Following the announcements of a number of the latest AI technologies at the GPU Technology Conference (GTC21), NVIDIA plans to share transformative technologies that will make impacts on various industries with global participants in the COMPUTEX keynote and forum.
In addition, NXP Semiconductors will share its vision and lead the Secure Edge and AI Empowerment discussions in fields such as Smart Home, Smart City, Smart Transportation, and Smart Manufacturing in the COMPUTEX Forum as well.
#COMPUTEXVirtual to build the intelligent platform for a personalized experience
Having partaken in every industry disruption within the last four decades, COMPUTEX now rides the digital transformation wave with tech pioneers. This year, COMPUTEX has chosen Appier, a Taiwanese unicorn startup listed in the Tokyo Stock Exchange, as its technology partner. Leveraging Appier’s AI and automation technologies to create the optimal digital user journey, #COMPUTEXVirtual helps exhibitors easily manage multiple marketing channels through a one-stop platform, while providing a more personalized interactive experience to all visitors. Exhibitors can reach people with the most relevant content and achieve optimal engagement to increase business collaboration opportunities with their target audiences.
#COMPUTEXVirtual and #InnoVEXVirtual online exhibitions are now open for registration. TAITRA will soon release more details on the upcoming COMPUTEX 2021 Hybrid.
-
#COMPUTEXVirtual Online Exhibition(Visitor Registration):
https://virtual.computextaipei.com.tw -
#COMPUTEXVirtual Online Exhibition(Exhibitor Registration):
https://events.taiwantrade.com/CVirtual01 -
#InnoVEXVirtual Online Exhibition(Exhibitor Registration):
https://events.taiwantrade.com/IVirtual0
For more updates:
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Hybrid:
As a pioneer in technology, COMPUTEX has been on the forefront in embracing digital transformation. COMPUTEX will launch the Online-Merge-Offline (OMO) exhibition platform "COMPUTEX 2021 Hybrid" in 2021. As the event organizer, the Taiwan External Trade Development Council (TAITRA) aims to deliver an exceptional exhibition experience by combining #COMPUTEXVirtual with the onsite exhibition. In collaborating with the Taiwanese unicorn startup, Appier, TAITRA is introducing AI computing capabilities to the exhibition to shape COMPUTEX as a global model.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005996/en/
Contact information
Press Contacts:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
